Vinn, in the short-medium term (say the next 5years) MLA's prospects rest solely on its ability to increase the number of clinics offering the procedure & subsequently the number of procedures done. Combined this with increasing the ~9mil revenue already generated from the OEM business and that's the foundation on which the SP will build from.
I would be disappointed as a shareholder if MLA sat around on the technology like you're suggesting (waiting for potential human application, or for it to be outdated by a more efficient procedure...). Any new products they can offer is another way in which MLA can diversify its revenue base, becoming a more solid company and appeal to a wider variety of investors.
The time to strike is now IMO, and MLA is building a great foundation on which to leverage off, including realigning and introducing new products in the OEM business and hopefully squeezing some additional margin out of it.
the one thing we can both probably agree on is the potential of MLA and the success this company is likely to have over the coming years.
Is going to take a lot more than 40c for me to even look at selling any of my holding!
MLA Price at posting:
42.5¢ Sentiment: LT Buy Disclosure: Held
